Back to results
US 2004/0082526 A1Published application
Macrolide antibiotics
AssigneeGlaxo Group Limited
InventorsDaniele Andreotti, Stefano Biondi, Sergio Lociuro
Life of this patent
Estimating the term…
Abstract
1 The present invention relates to 11,12γ lactone ketolides of formula (I), wherein R, R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.
Claims12
A compound of formula (I)
- 20
- wherein
- R is hydrogen, cyano or NR4R5;
- R1 is XR6;
- R2 is hydrogen or a hydroxyl protecting group;
- R3 is hydrogen or halogen;
- R6 is selected from:
- optionally substituted phenyl;
- optionally substituted 5 or 6 membered heteroaryl in which the 5-membered heteroaryl contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms,
- optionally substituted 5-6 membered heterocyclic,
- optionally substituted 9 to 10 membered fused bicyclic carbocyclic;
- or
- R6 is an optionally substituted 9 or 10 membered fused bicyclic heterocyclic having at least one heteroatom selected from oxygen, sulphur or nitrogen;
- X is a C1-10 alkylene, a C3-10 alkenylene or a C3-10 alkynylene chain wherein said chains are:
- +P2
- i) optionally interrupted by a bivalent radical group selected from —N(R5)—, —C(O)—, —S(O)n-, —N(R5)C(O)—, —C(O)N(R5)—,
- ii) optionally substituted by one or two groups selected from:
- C1-4 alkyl, oxo, C1-4 alkoxy, halogen, cyano, phenoxy, hydroxy, NR4R5;
- R4 is hydrogen, C1-4 alkyl or C(O)R5;
- R5 is hydrogen or C1-4 alkyl;
- n is 0 or an integer from 1 to 2;
- and pharmaceutically acceptable salts and solvates thereof.
19 more elements
A compound selected from:
- (11S,21R)-3-Decladinosyl-11,12-dideoxy-6-O-[(quinolin-3-yl)-propen-3-yl]-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]-erythromycin A;
- (11S)-3-Decladinosyl-11,12-dideoxy-6-O-[(quinolin-3-yl)propen-3-yl]-3-oxo-12,11-[oxycarbonyl-methylene]-erythromycin A;
- (11S,21R)-3-Decladinosyl-11,12-dideoxy-6-O-[(quinolin-5-yl)-propen-3-yl]-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]-erythromycin A;
- (11S,21R)-3-Decladinosyl-11,12-dideoxy-6-O-[(quinolin-6-yl)-propen-3-yl]-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]-erythromycin A;
- (11S,21R)-3-Decladinosyl-11,12-dideoxy-6-O-[(quinolin-7-yl)-propen-3-yl]-3-oxo-12,11-[oxycarbonyl-(cyano)methylene]-erythromycin A.
2 more elements
A process for the preparation of a compound as claimed in claim 1 which comprises:
- a) cyclisation of chlorine derivatives (IV), wherein R1a has the meaning defined in claim 1 for R1 or is a group convertible thereto, R2, R3 have the meanings defined in claim 1, R10 is a cladinose derivative of formula (III) or hydroxy, R11 is hydrogen or R11 together R10 is an oxygen atom,
- 21
- to produce a compound of formula (I) wherein R is cyano;
- b) elimination of the cyano group from a compound of formula (II), wherein R1a, R10 and R11 have the meaning as defined for compounds of formula (IV), R2, R3 have the meanings defined in claim 1,
- 22
- to produce compound of formula (I) wherein R is hydrogen;
- c) reacting amino compounds of formula (V) in which wherein R1a, R10 and R11 have the meaning as defined for compounds of formula (IV), R2, R3 have the meanings defined in claim 1,
- 23
- with a suitable alkylating agent of formula L-R4 (VI), wherein R4 is C1-4 alkyl and L is a suitable leaving group to produce a compound of formula(I) wherein R4 is C1-4alkyl and R5 is hydrogen or C1-4alkyl;
- d) reacting amino compounds of formula (V) wherein R1a, R10 and R11 have the meaning as defined for compounds of formula (II), R2, R3 have the meanings defined in claim 1, with an activated derivative of the acid HO(O)CR5 (VI a) to produce a compound of formula (I) wherein R is NHR4R5, R4 is C(O)R5;
- e) cyclisation of compounds of formula (VII) wherein R12 is a suitable nitrogen protecting group, R2, R3 have the meanings defined in claim 1, R1a, R10 and R11 have the meaning defined in formula (IV),
- 24
- in the presence of an organic base, followed by removal of the nitrogen protecting group, to produce a compound of formula(I) wherein R is NH2;
- f) reacting a compounds of formula (I), wherein R1a, R10 and R11 have the meaning as defined for compounds of formula (II), R3 is hydrogen and R2 is hydroxy protecting group, with a halogenating agent to produce a compound of formula(I) wherein R3 is halogen;
- thereafter, if required, subjecting the resulting compound to one or more of the following operations:
- i) conversion of the group R1a into the group R1;
- ii) hydrolysis of the cladinose derivative (III);
- iii) conversion of the 3-hydroxy group into the 3-oxo
- iv) removal of the protecting group R2 and
- v) conversion of the resultant compound of formula(I) into a pharmaceutically acceptable salt and solvates thereof.
17 more elements
Dependencies are inferred from the claim text.